4.6 Article

Selected commensal-related bacteria and Toll-like receptor 3 agonist combinatorial codes synergistically induce interleukin-12 production by dendritic cells to trigger a T helper type 1 polarizing programme

期刊

IMMUNOLOGY
卷 128, 期 1, 页码 e523-e531

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1365-2567.2008.03022.x

关键词

commensal bacteria; dendritic cells; interleukin-12; T helper type 1; Toll-like receptor

资金

  1. Danone Research and the Canadian Institute of Health Research [MOP-53152]

向作者/读者索取更多资源

P>Enteric infections remain a major health problem causing millions of deaths in developing countries. The interplay among the host intestinal epithelium, the mucosa-associated immune system and microbiota performs an essential role in gut homeostasis and protection against infectious diseases. Dendritic cells (DCs) play a key role in orchestrating protective immunity and tolerance in the gut. The mechanisms by which DCs adapt their responses and discriminate between virulent microbes and trillions of innocuous bacteria remain ill-defined. Here we investigated the effect of cross-talk between commensal-related bacteria (CB) and Toll-like receptor (TLR) agonists on DC activation and the outcome of the in vitro T helper response. Human monocyte-derived DCs were exposed to eight different Gram-positive or Gram-negative CB strains prior to activation with five different TLR agonists. The key polarizing cytokines interleukin (IL)-12p70, IL-10, IL-1 beta and IL-6 were quantified and the fate of naive T-cell differentiation was evaluated. We identified a unique combination of Lactobacillus casei and TLR3 signals that acted in synergy to selectively increase IL-12p70 secretion. Exposure to poly(I:C) converted L. casei-treated DCs into potent promoters of T helper type 1 (Th1) responses. We propose that DCs can integrate harmless and dangerous non-self signals delivered by viral products, to mount robust Th1 responses. Thus, in vivo DC targeting with selective probiotics may improve strategies for the management of enteric diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Comparing the impact of high-dose versus standard dose influenza vaccines on hospitalization cost for cardiovascular and respiratory diseases: Economic assessment in the US Veteran population during 5 respiratory seasons using an instrumental variable method

Robertus van Aalst, Ellyn M. Russo, Nabin Neupane, Salaheddin M. Mahmud, Jan Wilschut, Sandrine Samson, Ayman Chit, Maarten Postma, Yinong Young-Xu

Summary: In a study conducted in the US VHA population, high-dose influenza vaccination was found to significantly reduce hospitalization risks for cardiovascular and respiratory diseases. Reduction in hospitalizations for cardiovascular diseases contributed more to cost savings per high-dose recipient compared to respiratory diseases.

VACCINE (2021)

Article Immunology

The disease burden of influenza beyond respiratory illness

Alejandro E. Macias, Janet E. McElhaney, Sandra S. Chaves, Joshua Nealon, Marta C. Nunes, Sandrine Samson, Bruce T. Seet, Thomas Weinke, Hongjie Yu

Summary: Influenza, primarily known as a respiratory infection, also has broader consequences such as cardiovascular events, exacerbations of chronic illnesses, increased susceptibility to secondary infections, functional decline, and poor pregnancy outcomes. Understanding these broader consequences is crucial for assessing the full burden of influenza and the value of preventive measures among different populations.

VACCINE (2021)

Review Immunology

Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis

Jason K. H. Lee, Gary K. L. Lam, Thomas Shin, Sandrine Samson, David P. Greenberg, Ayman Chit

Summary: Evidence over 10 consecutive influenza seasons and in more than 34 million individuals aged >= 65 years suggests that HD-IIV3 is consistently more effective than SD-IIV at reducing influenza cases as well as influenza-associated clinical complications irrespective of circulating strain and antigenic match.

VACCINE (2021)

Article Critical Care Medicine

Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study

Ruvim Izikson, Daniel Brune, Jean-Sebastien Bolduc, Pierre Bourron, Marion Fournier, Tamala Mallett Moore, Aseem Pandey, Lucia Perez, Nessryne Sater, Anju Shrestha, Sophie Wague, Sandrine Samson

Summary: This study assessed the safety and immunogenicity of concomitant administration of high-dose quadrivalent influenza vaccine (QIV-HD) and mRNA-1273 vaccine booster in older adults. The results showed no safety concerns or immune interference in the coadministration group, supporting the recommendations for co-administration. The antibody responses to influenza and SARS-CoV-2 were similar between the coadministration and QIV-HD groups.

LANCET RESPIRATORY MEDICINE (2022)

Letter Biotechnology & Applied Microbiology

Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years

J. Kevin Yin, Stephanie Pepin, Robertus van Aalst, Matthew M. Loiacono, Sandrine I. Samson

Summary: The article challenges the recommendation of high-dose influenza vaccine and criticizes the authors of inaccurate numbers-needed-to-vaccinate (NNV) calculation. It emphasizes the importance of preferential recommendation for vaccines preventing influenza/complications and considering the impact of vaccination within the context of disease burden. To address the threat of the COVID-19 pandemic, the article suggests implementing concomitant influenza/COVID-19 vaccination to reduce the burden of co-circulation of influenza and SARS-CoV-2 viruses and increase vaccine coverage as per the WHO mandate.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Article Health Care Sciences & Services

Influence of Digital Intervention Messaging on Influenza Vaccination Rates Among Adults With Cardiovascular Disease in the United States: Decentralized Randomized Controlled Trial

Nell J. Marshall, Jennifer L. Lee, Jessica Schroeder, Wei-Nchih Lee, Jermyn See, Mohammad Madjid, Mrudula R. Munagala, John D. Piette, Litjen Tan, Orly Vardeny, Michael Greenberg, Jan Liska, Monica Mercer, Sandrine Samson

Summary: This personalized, evidence-based digital intervention proved effective in increasing vaccination rates among individuals with high-risk cardiovascular diseases. White and Asian individuals were more likely to get vaccinated, while the intervention had less impact on people of color.

JOURNAL OF MEDICAL INTERNET RESEARCH (2022)

Article Immunology

Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study

Jau-Yuan Chen, Szu-Min Hsieh, Shinn-Jang Hwang, Chiu-Shong Liu, Xiaoling Li, Marion Fournier, Ting-Yu Yeh, J. Kevin Yin, Sandrine Samson

Summary: This study evaluated the immunogenicity and safety of high-dose and standard-dose influenza vaccines in older adults in Taiwan. The results showed that the high-dose vaccine had higher immunogenicity for all four influenza strains compared to the standard-dose vaccine, and both vaccines had similar safety profiles.

VACCINE (2022)

Article Biotechnology & Applied Microbiology

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

Xiaoqiang Liu, Juliana Park, Shengli Xia, Bin Liang, Shuangmin Yang, Yanxia Wang, Olga Syrkina, Nathalie Lavis, Shuzhen Liu, Chenyan Zhao, Jian Ding, Jieqiong Hu, Sandrine Samson, Iris A. de Bruijn

Summary: The safety and immunogenicity of the quadrivalent, split-virion influenza vaccine (Shz QIV) developed in China were assessed. The vaccine showed good tolerability and induced immune responses in different age groups, demonstrating non-inferiority against various strains of influenza virus.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Letter Immunology

Letter to editor regarding a review of MF59-adjuvanted influenza vaccine by Gartner et al

J. Kevin Yin, Rebecca C. Harris, Matthew M. Loiacono, Ayman Chit, Sandrine I. Samson

VACCINE (2023)

Article Cardiac & Cardiovascular Systems

Nationwide Utilization of Danish Government Electronic letter system for increasing inFLUenza vaccine uptake (NUDGE-FLU): Study protocol for a nationwide randomized implementation trial

Niklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S. Bhatt, Simin Gharib Lee, Daniel Modin, Brian L. Claggett, Erica L. Dueger, Sandrine Samson, Matthew M. Loiacono, Lars Kober, Scott D. Solomon, Pradeesh Sivapalan, Jens Ulrik Staehr Jensen, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen

Summary: The NUDGE-FLU trial aims to investigate the effectiveness of digitally delivered behavioral nudges in increasing influenza vaccination uptake among older adults. It has randomized 964,870 Danish citizens aged 65 years and above to receive either no nudge or one of 9 electronic letters leveraging different behavioral science strategies. The trial will provide important insights into effective communication strategies to maximize vaccination uptake among high-risk groups.

AMERICAN HEART JOURNAL (2023)

Article Cardiac & Cardiovascular Systems

Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: Prespecified Analysis of the NUDGE-FLU Trial

Daniel Modin, Niklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S. Bhatt, Simin Gharib Lee, Brian L. Claggett, Erica L. Dueger, Sandrine I. Samson, Matthew M. Loiacono, Lars Kober, Scott D. Solomon, Pradeesh Sivapalan, Jens Ulrik Staehr Jensen, Cyril Jean-Marie Martel, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen

Summary: Digital behavioral nudges, such as electronic letters, emphasizing the potential cardiovascular benefits of influenza vaccination and using a reminder letter strategy, were found to be effective in increasing influenza vaccine uptake among older adults both with and without cardiovascular disease.

CIRCULATION (2023)

Article Cardiac & Cardiovascular Systems

Electronic nudges to increase influenza vaccination uptake among patients with heart failure: A pre-specified analysis of the NUDGE-FLU trial

Niklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S. Bhatt, Simin Gharib Lee, Daniel Modin, Brian L. Claggett, Erica L. Dueger, Sandrine Samson, Matthew M. Loiacono, Rebecca C. Harris, Lars Kober, Scott D. Solomon, Pradeesh Sivapalan, Jens Ulrik Staehr Jensen, Cyril Jean-Marie Martel, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen

Summary: This study analyzed the effects of two behavioral nudging letter strategies on influenza vaccination rates in patients with heart failure (HF). The results showed that the vaccination rate in HF patients was relatively low, but the behavioral nudging letter strategies were effective in increasing the vaccination rate and had no negative impact on the use of guideline-directed medical therapy (GDMT) in the long term.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Article Medicine, General & Internal

Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial

Niklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S. Bhatt, Simin Gharib Lee, Daniel Modin, Brian L. Claggett, Erica L. Dueger, Sandrine Samson, Matthew M. Loiacono, Lars Kober, Scott Solomon, Pradeesh Sivapalan, Jens Ulrik Staehr Jensen, Cyril Jean-Marie Martel, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen

Summary: This study investigated whether behavioural nudges delivered via a governmental electronic letter system could increase influenza vaccination uptake among older adults in Denmark. The results showed that sending an electronic letter highlighting potential cardiovascular benefits of vaccination or sending repeated letters at randomisation and at day 14 significantly improved vaccination rates.

LANCET (2023)

Review Immunology

High-dose influenza vaccine in older adults by age and seasonal characteristics: Systematic review and meta-analysis update

Jason K. H. Lee, Gary K. L. Lam, J. Kevin Yin, Matthew M. Loiacono, Sandrine I. Samson

Summary: This updated systematic review and meta-analysis assessed the relative performance of high-dose inactivated influenza vaccine (HD-IIV) and standard-dose influenza vaccines (SD-IIV) against influenza-associated outcomes in older adults (& GE;65 years). The analysis included studies conducted over 12 influenza seasons and showed that HD-IIV provided significantly better protection than SD-IIV against influenza-related outcomes. Subgroup analyses further demonstrated the consistent superiority of HD-IIV across different age groups and strains of influenza.

VACCINE: X (2023)

Article Medicine, Research & Experimental

Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial

Niklas Dyrby Johansen, Daniel Modin, Joshua Nealon, Sandrine Samson, Camille Salamand, Carsten Schade Larsen, Brian L. Claggett, Scott D. Solomon, Martin J. Landray, Gunnar H. Gislason, Lars Kober, Jens Ulrik Staehr Jensen, Pradeesh Sivapalan, Lasse Skafte Vestergaard, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen

Summary: This study aims to investigate the feasibility of a pragmatic clinical trial in Denmark comparing high-dose and standard-dose influenza vaccines. The study utilizes existing vaccination infrastructure and the Danish nationwide health registries for data collection. The results will provide valuable insights for future vaccine trials and other interventions.

PILOT AND FEASIBILITY STUDIES (2022)

暂无数据